Diagnostic tests for rheumatic disease: clinical utility revisited.
Establishing a diagnosis of systemic rheumatic disease requires an integration of a patient's symptoms, physical examination findings, and the results of diagnostic testing. There is often a temptation by clinicians to rely heavily on objective measures such as the presence or absence of an autoantibody. Medical textbooks and the medical literature may overestimate the diagnostic utility of many commonly ordered tests for rheumatic disease because the tests are usually analyzed among patients with established rheumatic disease rather than among patients with an uncertain cause of symptoms as is common in practice. Few diagnostic tests are highly sensitive, though the antinuclear antibody in systemic lupus erythematosus (SLE) and the erythrocyte sedimentation rate in temporal arteritis are notable exceptions. Conversely, few diagnostic tests are highly specific; anti-proteinase-3 and antimyeloperoxidase antibodies (types of antineutrophilic cytoplasmic antibodies) among patients with Wegener granulomatosis (and related vasculitides) and anti-double-stranded and anti-Smith antibodies among patients with SLE may be particularly helpful in the proper clinical settings due to their high specificity. Anticitrullinated cyclic protein (anti-CCP), a newly described autoantibody that may be highly specific for rheumatoid arthritis, requires additional study as its utility in clinical practice is uncertain.
Shmerling
Robert H
RH
Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston MA, USA. rshmerli@bidmc.harvard.edu
D000974:Antibodies, Antinuclear / Q000302:isolation & purification; D001799:Blood Sedimentation; D002097:C-Reactive Protein / Q000378:metabolism; D003937:Diagnosis, Differential; D006801:Humans; D011237:Predictive Value of Tests; D012216:Rheumatic Diseases / Q000175:diagnosis*; D012217:Rheumatoid Factor / Q000097:blood
D000974:Antibodies, Antinuclear; D002097:C-Reactive Protein; D012217:Rheumatoid Factor